Study did not meet its primary endpoint DUBLIN, Ireland and CHICAGO, June 01, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today...
Author: @admin
Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with several healthcare-focused institutional investors, including Fidelity Management & Research...
Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)
If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA European Commission decision anticipated in the second half of 2020 DUBLIN,...
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on...
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation
SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial...
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Financing advances clinical development of two innovative product candidates for the treatment of life-threatening diseases affecting patients with compromised immune systems SAN DIEGO – May 19, 2020 – Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that it has closed a...
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
Completes Enrollment of Phase 2 Candida Trial Treats First Patients in Phase 2 Trials in Aspergillus and Candida auris Infections SAN DIEGO – May 19, 2020 – Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has advanced development of...
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent
Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines DUBLIN, Ireland, May 18, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Iterum Therapeutics Reports First Quarter 2020 Financial Results
–Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 — — Raised $51.6 million through a private placement with new and existing investors — DUBLIN, Ireland and CHICAGO, May 14, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company...
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2020, and provided an update on its corporate activities and product...